Estimation of Interleukin-1β Promoter (−31 C/T and −511 T/C) Polymorphisms and Its Level in Coronary Artery Disease Patients
- Resource Type
- Authors
- Chelapram K. Firoz; Salwa Hindawi; Shams Tabrez; Ghazi A. Damanhouri; Syed Kashif Zaidi; Shazi Shakil; Nasimudeen R. Jabir
- Source
- Journal of Cellular Biochemistry. 118:2977-2982
- Subject
- 0301 basic medicine
medicine.medical_specialty
medicine.medical_treatment
Population
Single-nucleotide polymorphism
Biochemistry
Gastroenterology
Coronary artery disease
03 medical and health sciences
symbols.namesake
Internal medicine
medicine
SNP
education
Molecular Biology
Genetics
Sanger sequencing
education.field_of_study
business.industry
Haplotype
Promoter
Cell Biology
medicine.disease
030104 developmental biology
Cytokine
symbols
business
- Language
- ISSN
- 0730-2312
2977-2982
Interleukin-1β (IL-1β) is an inflammation-causing cytokine that exerts several unique biological effects and could lead to future adverse events of CAD. The piece of work presented herein is aimed at investigating possible association of IL-1β levels to its polymorphic site viz. -511 and -31 at promoter region in Saudi CAD patients. The study included 155 confirmed CAD patients and 80 healthy control individuals both men and women. Concentration of IL-1β in the patients' serum was measured by ELISA method. For single nucleotide polymorphism (SNP) analysis, sanger method of DNA sequencing was followed. We observed variable numbers of SNPs at -31 C/T and -511 T/C promoter regions in Saudi patients suffering from CAD in comparison to the control set of individuals. However, the changes in the number of SNP-hotspots were determined to be non-significant with reference to the control set. The haplotype analysis at -31 and -511 also did not show any significant changes between control and CAD patients. Moreover, serum IL-1β levels were observed to be expressively higher in patients suffering from CAD (P